| scholarly article | Q13442814 |
| P356 | DOI | 10.3747/CO.22.2383 |
| P8608 | Fatcat ID | release_6cufw2fl4vbynpnu3hkkcsipwq |
| P932 | PMC publication ID | 4530821 |
| P698 | PubMed publication ID | 26300674 |
| P5875 | ResearchGate publication ID | 281551981 |
| P50 | author | Daniel Rayson | Q109926388 |
| Chris D Skedgel | Q40585686 | ||
| P2093 | author name string | N W D Lamond | |
| T Younis | |||
| P2860 | cites work | Bisphosphonates and other bone agents for breast cancer | Q24203656 |
| When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology | Q24645229 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. | Q51522634 | ||
| Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. | Q51522929 | ||
| Estimates of the lifetime costs of breast cancer treatment in Canada. | Q52079961 | ||
| Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer | Q79344674 | ||
| Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole | Q80081707 | ||
| Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results | Q87419544 | ||
| Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy | Q33787731 | ||
| Development of WHO guidelines on generalized cost-effectiveness analysis | Q33903387 | ||
| Willingness to pay for a quality-adjusted life year: in search of a standard | Q33993542 | ||
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | Q34382805 | ||
| Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis | Q34583705 | ||
| Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole | Q34783300 | ||
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer. | Q34943802 | ||
| Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer | Q34962888 | ||
| Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. | Q35584343 | ||
| Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis | Q37418209 | ||
| Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. | Q37532912 | ||
| Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment | Q37854287 | ||
| Potential anticancer properties of bisphosphonates: insights from preclinical studies | Q37921805 | ||
| American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer | Q37928808 | ||
| The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials | Q37958566 | ||
| American Society of Clinical Oncology guidance statement: the cost of cancer care | Q39965070 | ||
| Willingness to pay for a QALY: past, present and future. | Q40024139 | ||
| Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. | Q40482876 | ||
| Breast-cancer adjuvant therapy with zoledronic acid | Q42620139 | ||
| Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study | Q42970092 | ||
| Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. | Q43231774 | ||
| Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation | Q43682728 | ||
| Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). | Q43844327 | ||
| Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients | Q44507167 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda | Q44635849 | ||
| A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer | Q44795543 | ||
| Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial | Q45496960 | ||
| Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. | Q46689583 | ||
| Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. | Q46801197 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | zoledronic acid | Q218507 |
| P304 | page(s) | e246-53 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Current Oncology | Q3498968 |
| P1476 | title | Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels | |
| P478 | volume | 22 |
Search more.